Outcome of Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Based On Early Molecular Response and Factors Associated with Early Response: 4-Year Follow-up Data From Enestnd (Evaluating Nilotinib Efficacy and Safety in Clinical Trials Newly Diagnosed Patients)

被引：18

作者：

Hochhaus, Andreas ^{[1
]}

Hughes, Timothy P. ^{[2
]}

Saglio, Giuseppe ^{[3
]}

Guilhot, Francois ^{[4
]}

Al-Ali, Haifa Kathrin ^{[5
]}

Rosti, Giantonio ^{[6
]}

Nakaseko, Chiaki ^{[7
]}

De Souza, Carmino Antonio ^{[8
]}

Kemp, Charisse ^{[9
]}

Fan, Xiaolin ^{[9
]}

Hoenekopp, Albert ^{[10
]}

Larson, Richard A. ^{[11
]}

Kantarjian, Hagop M. ^{[12
]}

机构：

[1] Univ Klinikum Jena, Dept Hematol & Oncol, Jena, Germany

[2] Royal Adelaide Hosp, SA Pathol, Dept Haematol, Adelaide, SA 5000, Australia

[3] Univ Turin, San Luigi Gonzaga Hosp, Dept Clin & Biol Sci, Turin, Italy

[4] Univ Hosp, CHU Poitiers, Inserm Cic 802, Poitiers, France

[5] Univ Leipzig, D-04109 Leipzig, Germany

[6] Univ Bologna, Dept Hematol & Med Oncol, Bologna, Italy

[7] Chiba Univ Hosp, Dept Hematol, Chiba, Japan

[8] Univ Estadual Campinas, Campinas, SP, Brazil

[9] Novartis Pharmaceut, E Hanover, NJ USA

[10] Novartis Pharma AG, Basel, Switzerland

[11] Univ Chicago, Chicago, IL 60637 USA

[12] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

关键词：

D O I：

10.1182/blood.V120.21.167.167

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

167

引用

页数：3